Instrument Inactif

Autres langues Fibrocell Science, Inc.

Actions

US3157214079

Recherche biotechnologique et médicale

Autres langues

17/12/19	Fibrocell Science : Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science
16/12/19	Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index
13/12/19	FIBROCELL SCIENCE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
13/12/19	Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index
13/12/19	Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc..
10/12/19	FIBROCELL SCIENCE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
22/11/19	FIBROCELL SCIENCE, INC. : Other Events (form 8-K)
14/11/19	Fibrocell Science, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
17/09/19	FIBROCELL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fibrocell Science, Inc. - FCSC
12/09/19	Castle Creek Pharmaceutical Holdings, Inc. entered into a definitive agreement to acquire Fibrocell Science, Inc. for $63.3 million.
22/08/19	Fibrocell Science, Inc Appoints Sean D. Buckley as Chief Financial Officer
14/08/19	Fibrocell Science, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
14/08/19	Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
29/05/19	Fibrocell Science, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
29/05/19	Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
15/05/19	Fibrocell Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019
15/04/19	Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
15/04/19	Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
27/03/19	Fibrocell Science, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018
27/03/19	Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
27/03/19	Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
27/03/19	Fibrocell Science, Inc. Auditor Raises 'Going Concern' Doubt
06/02/19	Fibrocell to Present at 21st Annual BIO CEO & Investor Conference
16/01/19	Fibrocell to Present at Phacilitate Leaders World 2019
11/12/18	Fibrocell Science, Inc. announced that it has received $0.9 million in funding from EB Research Partnership, Inc., Endowment Arm, Epidermolysis Bullosa Medical Research Foundation, Endowment Arm